Cancer Prevention Research CM8 AM No Deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Prevention Research 1, 316, October 1, 2008. doi: 10.1158/1940-6207.CAPR-07-0002
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Perspective on this Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, H.
Right arrow Articles by Koo, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, H.
Right arrow Articles by Koo, J. S.
Related Collections
Right arrow Oncogenesis
Right arrow Oncogenesis: In Vitro
Right arrow Preclinical Intervention: In Vitro: Drugs, Mechanisms
Right arrowCommentary

Research Articles

Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-{kappa}B–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis

Hongxia Sun, Wen-Cheng Chung, Seung-Hee Ryu, Zhenlin Ju, Hai T. Tran, Edward Kim, Jonathan M. Kurie and Ja Seok Koo

Authors' Affiliation: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Ja Seok Koo, Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-6363; Fax: 713-794-5997; E-mail: jskoo{at}mdanderson.org.


The recognition of the importance of angiogenesis in tumor progression has led to the development of antiangiogenesis as a new strategy for cancer treatment and prevention. By modulating tumor microenvironment and inducing angiogenesis, the proinflammatory cytokine interleukine (IL)-1β has been reported to promote tumor development. However, the factors mediating IL-1β–induced angiogenesis in non–small cell lung cancer (NSCLC) and the regulation of these angiogenic factors by IL-1β are less clear. Here, we report that IL-1β up-regulated an array of proangiogenic CXC chemokine genes in the NSCLC cell line A549 and in normal human tracheobronchial epithelium cells, as determined by microarray analysis. Further analysis revealed that IL-1β induced much higher protein levels of CXC chemokines in NSCLC cells than in normal human tracheobronchial epithelium cells. Conditioned medium from IL-1β–treated A549 cells markedly increased endothelial cell migration, which was suppressed by neutralizing antibodies against CXCL5 and CXCR2. We also found that IL-1β–induced CXC chemokine gene overexpression in NSCLC cells was abrogated with the knockdown of cyclic AMP-responsive element binding protein (CREB) or nuclear factor {kappa}B (NF-{kappa}B). Moreover, the expression of the CXC chemokine genes as well as CREB and NF-{kappa}B activities was greatly increased in the tumorigenic NSCLC cell line compared with normal, premalignant immortalized or nontumorigenic cell lines. A disruptor of the interaction between CREB-binding protein and transcription factors such as CREB and NF-{kappa}B, 2-naphthol-AS-E-phosphate (KG-501), inhibited IL-1β–induced CXC chemokine gene expression and angiogenic activity in NSCLC. We propose that targeting CREB or NF-{kappa}B using small-molecule inhibitors, such as KG-501, holds promise as a preventive and/or therapeutic approach for NSCLC.

Key Words: Angiogenesis • chemoprevention • CREB • NF-{kappa}B • CXC Chemokine • lung cancer


Commentary

Out of the Shadows: CXC Chemokines in Promoting Aberrant Lung Cancer Angiogenesis
Robert M. Strieter
Cancer Prevention Research 2008 1: 305-307. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
R. M. Strieter
Out of the Shadows: CXC Chemokines in Promoting Aberrant Lung Cancer Angiogenesis
Cancer Prevention Research, October 1, 2008; 1(5): 305 - 307.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.